Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioEBIT MarginEBITDA MarginEBT MarginEnterprise ValueInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Innate Pharma (IPHA) Net Margin (2019 - 2025)

Historic Net Margin for Innate Pharma (IPHA) over the last 7 years, with Q2 2025 value amounting to 807.14%.

  • Innate Pharma's Net Margin fell 5147300.0% to 807.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 210.96%, marking a year-over-year decrease of 2106800.0%. This contributed to the annual value of 43.9% for FY2024, which is 402900.0% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Net Margin is 807.14%, which was down 5147300.0% from 430.44% recorded in Q4 2024.
  • Over the past 5 years, Innate Pharma's Net Margin peaked at 1.61% during Q2 2023, and registered a low of 947.58% during Q4 2021.
  • Moreover, its 5-year median value for Net Margin was 201.73% (2023), whereas its average is 323.44%.
  • Per our database at Business Quant, Innate Pharma's Net Margin crashed by -5573600bps in 2021 and then skyrocketed by 9474700bps in 2022.
  • Innate Pharma's Net Margin (Quarter) stood at 947.58% in 2021, then soared by 100bps to 0.11% in 2022, then plummeted by -101576bps to 111.05% in 2023, then tumbled by -288bps to 430.44% in 2024, then tumbled by -88bps to 807.14% in 2025.
  • Its Net Margin stands at 807.14% for Q2 2025, versus 430.44% for Q4 2024 and 292.4% for Q2 2024.